J.P. Morgan Notebook, Jan. 14: AbbVie, AstraZeneca, Juno & Bluebird

 
• By Jessica Merrill and Emily Hayes

Day three of “The Pink Sheet” DAILY’s round-up of news and notes from the 2015 J.P. Morgan Healthcare Conference in San Francisco. Pricing remains center stage, with AbbVie weighing in on HCV and AstraZeneca’s Soriot predicting cost-competition in oncology. CAR-T continues to advance, with updates from Juno and bluebird.

More from Clinical Trials

More from R&D